Hester BiosciencesBOM:524669 +0.73%79 Gross Margin % is 80.57% as of Mar. 2026, which is 17% above its 10-year median of 68.60. GuruFocus rates BOM:524669 with a GF Score™ of 79/100 and a GF Value™ of ₹1,889.64 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 943 Drug Manufacturers companies, Hester Biosciences ranks better than 88.12% on this metric.
The historical rank and industry rank for Hester Biosciences's Gross Margin % or its related term are showing as below:
BOM:524669'
s Gross Margin % Range Over the Past 10 Years
Min: 63.82 Med: 68.6 Max: 79.05
Current: 75.36
During the past 13 years, the highestGross Margin % of Hester Biosciences was 79.05%. The lowest was 63.82%. And the median was 68.60%.
BOM:524669's Gross Margin % is ranked better than 88.12% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs BOM:524669: 75.36
Hester Biosciences had a gross margin of 80.57% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Hester Biosciences was -0.60% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Hester Biosciences had a gross margin of 80.57% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Hester Biosciences Gross Margin % Related Terms
Hester Biosciences Gross Margin % Historical Data
* Premium members only.
The historical data trend for Hester Biosciences's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524669 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hester Biosciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hester Biosciences Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hester Biosciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Hester Biosciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Hester Biosciences (BOM:524669) has a Gross Margin % of 80.57% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Hester Biosciences and its competitors. This is 17% above median its historical median of 68.60. Over the past decade, Hester Biosciences' Gross Margin % has ranged from 63.82 to 79.05. According to the industry distribution chart, Hester Biosciences ranks #112 out of 943 companies in the Drug Manufacturers industry, placing it in the top 11.9%.
Is Hester Biosciences' Gross Margin % too high?
Hester Biosciences' current Gross Margin % of 80.57% is 17% above median its 10-year median of 68.60. Over the past 10 years, this metric has ranged from a low of 63.82 to a high of 79.05. The Drug Manufacturers industry median Gross Margin % is 48.54. Hester Biosciences' value of 80.57% is 66% above this industry median. Based on the distribution chart, Hester Biosciences ranks #112 out of 943 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hester Biosciences has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hester Biosciences' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hester Biosciences ranks #112 out of 943 companies for Gross Margin %. This places Hester Biosciences in the top 12% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Hester Biosciences' value of 80.57% is 66% above this benchmark. Historically, Hester Biosciences' own Gross Margin % has ranged from 63.82 to 79.05 over the past decade. While the company's 10-year median is 68.60 vs. the industry median of 48.54, Hester Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hester Biosciences's current Gross Margin % of 80.57% is 66% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Hester Biosciences and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hester Biosciences's current Gross Margin % is 80.57%, which is 17% above median its own 10-year median of 68.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hester Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Hester Biosciences (BOM:524669) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,889.64, compared to a current price of ₹2,109.40 — trading 11.6% above its estimated fair value. The current Gross Margin % is 80.57%, which is 17% above median its 10-year median of 68.60 and 66% above the Drug Manufacturers industry median of 48.54. Hester Biosciences' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Hester Biosciences (BOM:524669), the current Gross Margin % is 80.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hester Biosciences (BOM:524669) Overvalued in 2026?
Based on GuruFocus' analysis, Hester Biosciences stock appears to be overvalued.
The current stock price of ₹2,109.40 is trading 11.6% above its estimated GF Value™ of ₹1,889.64.
GuruFocus considers Hester Biosciences to be Modestly Overvalued.
Key valuation signals for BOM:524669:
Gross Margin %: 80.57% (17% above median its 10-year median of 68.60)
GF Value™: ₹1,889.64 vs. price of ₹2,109.40 (11.6% above fair value)
Industry Position: 66% above the Drug Manufacturers median (#112 of 943)
No single metric tells the full story. See the BOM:524669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hester Biosciences Ltd is an India-based animal healthcare company. It is principally engaged in the manufacturing of veterinary vaccines and trading of veterinary health products such as goat pox vaccine, PPR vaccines, etc. The group has two principal operating and reporting segments, viz. Poultry healthcare and Animal healthcare. Maximum revenue is generated from the Poultry Healthcare segment, which offers various solutions encompassing vaccines, health products, and feed supplements, supported and packaged by its diagnostic services, R&D, quality standards, and field support, to help farmers protect flock health, enhance productivity, and drive long-term farm sustainability. Geographically, it generates maximum revenue within India, and also exports its products to other markets.
79GF Score
Get the complete analysis for BOM:524669
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524669 has been successfully added to your 
